Pulmonary

Principal Investigator: Sandra Weibel, MD

A Randomized, Double-blind, Placebo-Controlled, Phase II Multicenter Trial of a Monoclonal Antibody to CD20 (Rituximab) for the Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)

Principal Investigator: Michael Scharf, MD

A Post-marketing Observational Study to Assess Respiratory Tract Adverse Events in Pulmonary Arterial Hypertension Patients Treated with Tyvaso® (Treprostinil) Inhalation Solution

Principal Investigator: Mani S. Kavuru, MD

A 16-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) Treatment in Patients With Moderate to Severe Asthma

Principal Investigator: Michael Baram, MD

Evaluating the Use of Polymyxin B Hemoperfusion in a Randomized Controlled Trial of Adults Treated for Endotoxemia and Septic Shock

Principal Investigator: Michael Scharf, MD

A Multicenter, Double-Blind, Placebo-Controlled Phase 3 Study to Demonstrate the Efficacy and Safety of ACT-293987 in Patients with Pulmonary Arterial Hypertension

Principal Investigator: Michael Scharf, MD

Registry to Prospectively Describe Use of Epoprostenol for Injection ("RTS Epoprostenol") in Patients with Pulmonary Arterial Hypertension

*No Longer Enrolling New Patients